Compass Pathways Analyst Ratings
Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating
Compass Pathways Analyst Ratings
Buy Rating Affirmed for COMPASS Pathways Amid Strong Financials and Promising Clinical Trials
Analysts Offer Insights on Healthcare Companies: Rapid Micro Biosystems (RPID), COMPASS Pathways (CMPS) and Harrow Health (HROW)
COMPASS Pathways' COMP360 Shows Promise in Mental Health: A Buy Rating Amid Positive Trial Outcomes and Strategic R&D Leadership
Compass Pathways Analyst Ratings
Compass Pathways Analyst Ratings
Compass Pathways Analyst Ratings
Atai Life Sciences Upgraded at Maxim on Beckley Investment
Compass Pathways Analyst Ratings
Buy Rating on COMPASS Pathways: COMP360's Market Potential and Promising TRD Therapy
Buy Rating Affirmed for COMPASS Pathways Amid Promising Neuropsychiatric Treatment Advances
COMPASS Pathways: A Buy Recommendation Anchored by Strong Cash Reserves and Strategic Collaborations
HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target
Compass Pathways Analyst Ratings
Buy Rating Affirmed for COMPASS Pathways Amid Strategic Advances and Promising Clinical Trials
Buy Rating on COMPASS Pathways: Overreaction Creates Investment Opportunity Amid Positive Trial Prospects
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and COMPASS Pathways (CMPS)
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and BioNTech SE (BNTX)